ANKE BIO: Exclusive agent product recombinant follicle-stimulating hormone-CTP fusion protein injection approved for market launch
ANKE BIO announced that the product recombinant human follicle-stimulating hormone-CTP fusion protein injection, exclusively represented by Suzhou Shengji Pharmaceutical Co., Ltd. in mainland China and Hong Kong, Macau, and Taiwan, has been approved for marketing by the National Medical Products Administration. This product is the first long-acting recombinant human follicle-stimulating hormone approved in China
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments